Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Jan 08, 2019 8:27am
113 Views
Post# 29199088

RE:RE:RE:RE:RE:RE:Slides up bio tech

RE:RE:RE:RE:RE:RE:Slides up bio tech Yeah, unfortunately my president thinks out loud a lot too. I'm scared of what might come out of his mouth tonight. But seriously.....

December 31, 2018 = end of 2018 = Sept-Nov guidance on end of dosing/hitting 250 events; 2-3 months was the guidance on adjudication, after which comes top-line. So end of year dosing = very likely Q1 topline. 

Today is January 8, 2019 = 8 days past end of 2018. 250 events/end of dosing not reach yet. But we're only 8 days off of the Sept-Nov guidance! The MD&A, Dec and Jan updates changed the wording to H1 end of dosing and/or H1 trial completion. Q1 is still in H1. If one takes the 3 month number in the 2-3 month adjuciation range, then one is into Q2 assuming dosing ends soon. Big deal! 

Mountains out of mole hills. The sky is falling! 

BearDownAZ
Bullboard Posts